Categories: Health

Intas Pharmaceuticals Launches HETRONIFLY (Serplulimab), India’s First Novel Immunotherapy for Advanced Small Cell Lung Cancer

AHMEDABAD, India, Aug. 5, 2025 /PRNewswire/ — Intas Pharmaceuticals has launched HETRONIFLY™ (Serplulimab), the first PD-1 inhibitor globally approved for the treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC), in the Indian market. This marks another major milestone, following the successful Launch in Europe.

- Advertisement -

This launch follows a strategic licensing agreement between Intas Pharmaceuticals Limited and Shanghai Henlius Biotech, Inc., further strengthening Intas’ oncology portfolio and reinforcing its commitment to delivering cutting-edge therapies to patients in India.

- Advertisement -

Serplulimab is the first PD-1 inhibitor worldwide to receive approval for ES-SCLC, and is currently present in over 40 countries, including key European markets. Its efficacy is supported by the landmark ASTRUM-005 trial, which demonstrated a 40% reduction in the risk of death and remarkably higher overall survival rate versus the current standard-of-care Chemotherapy regimen. Notably, Serplulimab achieved an ESMO-MCBS score of 4/5—the highest among current immunotherapies, signifying highest clinical benefit in this indication.

- Advertisement -

The novel humanized mAb has a unique dual-blockade mechanism of PD-L1 and PD-L2, along with the highest PD-1 internalization, which sets a new benchmark in deep immune engagement for solid tumors. Globally, Serplulimab has been administered to over a lakh patients across a range of malignancies including SCLC, NSCLC, ESCC, and MSI-high cancers.

- Advertisement -

Despite the promise of immuno-oncology, cost remains a significant barrier in India. HETRONIFLY™, introduced at approximately 75% lower cost than the currently available immunotherapies for this indication, underscores Intas’ commitment to providing high-quality innovative therapies at affordable prices to cancer patients in India.

- Advertisement -

Commenting on the launch, Binish Chudgar, Chairman & Managing Director of Intas Pharmaceuticals said, “The launch of HETRONIFLY™ reinforces our strategic position in oncology and reflects Intas’ commitment to accelerating access to globally validated therapies. It aligns with our operating model of delivering high-impact innovations to the Indian market with speed and cost-efficiency.”

- Advertisement -

Logo: https://mma.prnewswire.com/media/2514170/4930499/Intas_Accord_Logo.jpg

- Advertisement -

 

- Advertisement -

View original content:https://www.prnewswire.com/in/news-releases/intas-pharmaceuticals-launches-hetronifly-serplulimab-indias-first-novel-immunotherapy-for-advanced-small-cell-lung-cancer-302522015.html

- Advertisement -
PRNW Agency

Recent Posts

China Pavilion at Osaka Expo 2025 wins the Gold Award! Unilumin provides a comprehensive multimedia solution

OSAKA, Japan, Oct. 30, 2025 /PRNewswire/ -- On the evening of October 12, 2025, the…

39 minutes ago

Parcel Perform Defines ‘GEO’ for E-Commerce with Launch of AI Commerce Visibility

Brands can now track, analyze and optimize their visibility across AI shopping agents like ChatGPT, Perplexity,…

39 minutes ago

Ascentage Pharma to Participate in Two Upcoming Investor Conferences in November 2025

October 29, 2025 20:00 ET  | Source: ASCENTAGE PHARMA GROUP INTERNATIONAL ROCKVILLE, Md. and SUZHOU,…

4 hours ago

Specialist Direct’s Mira Partners with dacadoo to Transform Recovery Management and Wellness Outcomes

Strategic integration of advanced health engagement technology to enhance recovery journeys and promote healthier lifestyles…

4 hours ago

Chull OTT Launches in India: USA-Based Flickfusion Media INC Introduces A Next-Gen Streaming Platform for Regional and Global Storytelling

Flickfusion Media INC, a USA-based digital media company, today announced the official launch of Chull…

5 hours ago

MAAC Concludes its 6.0 Edition of the 100-Hour Tech Challenge in 3D Animation Film and Mobile Filmmaking

Over 180+ entries and over 900 participants from MAAC centers across India joined the thrilling…

5 hours ago